CSIMarket
 


Kyto Technology And Life Science Inc   (KBPH)
Other Ticker:  
 

Kyto Technology And Life Science Inc 's Quick Ratio

KBPH's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Kyto Technology And Life Science Inc 's Cash & cash equivalent, this led to improvement in Kyto Technology And Life Science Inc 's Quick Ratio to 3.74, Quick Ratio remained below Kyto Technology And Life Science Inc average.

Within Major Pharmaceutical Preparations industry 364 other companies have achieved higher Quick Ratio than Kyto Technology And Life Science Inc in second quarter 2021. While Quick Ratio total ranking has improved so far during the II Quarter 2021 to 1342, from total ranking in the first quarter 2021 at 1521.

Explain Quick Ratio?
How much Cash & cash equivalents KBPH´s has?
What are KBPH´s Current Liabilities?


KBPH Quick Ratio (Sep 30 2021)
II. Quarter
(Jun 30 2021)
I. Quarter
(Mar 31 2021)
IV. Quarter
(Dec 31 2020)
III. Quarter
(Sep 30 2020)
II. Quarter
Y / Y Current Liabilities Change 67.33 % 394.59 % 4373.52 % 20.96 % -23.48 %
Y / Y Cash & cash equivalent Change -20.46 % 281.15 % 4159.59 % 34.65 % 66.69 %
Quick Ratio MRQ 3.74 2.63 1 6.78 7.87
KBPH's Total Ranking # 1342 # 1521 # 2209 # 2204 # 534
Seq. Current Liabilities Change -53.83 % -87.26 % 1628.04 % 64.55 % 36.49 %
Seq. Cash & cash equivalent Change -34.35 % -66.51 % 155.03 % 41.86 % 214.61 %



Quick Ratio second quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 365
Healthcare Sector # 640
Overall Market # 1342


Quick Ratio Statistics
High Average Low
13.83 4.63 0.97
(Jun 30 2018)   (Dec 31 2018)




Financial Statements
Kyto Technology And Life Science Inc 's Current Liabilities $ 0 Millions Visit KBPH's Balance sheet
Kyto Technology And Life Science Inc 's Cash & cash equivalent $ 0 Millions Visit KBPH's Balance sheet
Source of KBPH's Sales Visit KBPH's Sales by Geography


Cumulative Kyto Technology And Life Science Inc 's Quick Ratio

KBPH's Quick Ratio for the trailling 12 Months

KBPH Quick Ratio

(Sep 30 2021)
II. Quarter
(Jun 30 2021)
I. Quarter
(Mar 31 2021)
IV. Quarter
(Dec 31 2020)
III. Quarter
(Sep 30 2020)
II. Quarter
Y / Y Current Liabilities TTM Growth 67.33 % 394.59 % 4373.52 % 20.96 % -23.48 %
Y / Y Cash & cash equivalent TTM Growth -20.46 % 281.15 % 4159.59 % 34.65 % 66.69 %
Quick Ratio TTM 1.57 1.64 1.57 5.53 5.18
Total Ranking TTM # 1109 # 1947 # 1405 # 1939 # 455
Seq. Current Liabilities TTM Growth -53.83 % -87.26 % 1628.04 % 64.55 % 36.49 %
Seq. Cash & cash equivalent TTM Growth -34.35 % -66.51 % 155.03 % 41.86 % 214.61 %


On the trailing twelve months basis Due to drop in Current Liabilities in the II Quarter 2021 to $0.08 millions, cumulative Quick Ratio decreased to 1.57 below the Kyto Technology And Life Science Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 375 other companies have achieved higher Quick Ratio than Kyto Technology And Life Science Inc . While Quick Ratio overall ranking has improved so far to 1109, from total ranking during the twelve months ending first quarter 2021 at 1947.

Explain Quick Ratio?
How much Cash & cash equivalents KBPH´s has?
What are KBPH´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 376
Healthcare Sector # 638
Within the Market # 1109


trailing twelve months Quick Ratio Statistics
High Average Low
5.53 3.43 0.23
(Dec 31 2020)   (Dec 31 2018)




Companies with similar Quick Ratio in the quarter ending Sep 30 2021, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2021 MRQ Cash & cash equivalentSep 30 2021 MRQ Current Liabilities
Morphic Holding inc   10.24 $ 427.576  Millions$ 41.764  Millions
Gossamer Bio Inc   10.20 $ 366.020  Millions$ 35.896  Millions
Homology Medicines Inc  10.03 $ 187.551  Millions$ 18.705  Millions
Enveric Biosciences Inc   9.92 $ 21.448  Millions$ 2.163  Millions
Seelos Therapeutics inc   9.87 $ 76.833  Millions$ 7.783  Millions
Sio Gene Therapies Inc   9.87 $ 101.695  Millions$ 10.308  Millions
Benitec Biopharma Inc   9.84 $ 15.752  Millions$ 1.601  Millions
Cymabay Therapeutics Inc   9.69 $ 113.788  Millions$ 11.741  Millions
Tempest Therapeutics Inc   9.63 $ 59.716  Millions$ 6.203  Millions
Adicet Bio Inc   9.60 $ 192.226  Millions$ 20.032  Millions
Intra cellular Therapies Inc   9.57 $ 477.284  Millions$ 49.896  Millions
Atreca inc   9.46 $ 152.886  Millions$ 16.155  Millions
Mirati Therapeutics Inc   9.46 $ 1,154.418  Millions$ 122.079  Millions
Zentalis Pharmaceuticals Inc   9.31 $ 366.791  Millions$ 39.415  Millions
Landos Biopharma Inc   9.25 $ 102.670  Millions$ 11.095  Millions
Cryoport inc   9.25 $ 350.437  Millions$ 37.884  Millions
Alzamend Neuro Inc   9.20 $ 13.573  Millions$ 1.476  Millions
Marinus Pharmaceuticals Inc   9.16 $ 145.101  Millions$ 15.848  Millions
Akero Therapeutics Inc   9.14 $ 215.081  Millions$ 23.540  Millions
Gt Biopharma Inc   9.11 $ 35.713  Millions$ 3.922  Millions
Liquidia Corporation  9.07 $ 64.054  Millions$ 7.064  Millions
F star Therapeutics Inc   9.04 $ 71.050  Millions$ 7.859  Millions
Hoth Therapeutics Inc   9.01 $ 14.477  Millions$ 1.607  Millions
Bolt Biotherapeutics Inc   8.98 $ 212.893  Millions$ 23.695  Millions
Ligand Pharmaceuticals Incorporated  8.90 $ 323.211  Millions$ 36.297  Millions
Concert Pharmaceuticals Inc   8.84 $ 106.223  Millions$ 12.021  Millions
Aeterna Zentaris Inc   8.71 $ 67.661  Millions$ 7.766  Millions
Bicycle Therapeutics Plc  8.60 $ 259.524  Millions$ 30.177  Millions
Ocuphire Pharma Inc   8.58 $ 22.633  Millions$ 2.638  Millions
Y mabs Therapeutics inc   8.51 $ 215.730  Millions$ 25.359  Millions

Date modified: 2022-03-01T22:51:15+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com